See more : American Vanguard Corporation (AVD) Income Statement Analysis – Financial Results
Complete financial analysis of Lexicon Pharmaceuticals, Inc. (LXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexicon Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lyka Labs Limited (LYKALABS.BO) Income Statement Analysis – Financial Results
- Idaho Strategic Resources, Inc. (NJMC) Income Statement Analysis – Financial Results
- Kaleyra, Inc. (KLR-WT) Income Statement Analysis – Financial Results
- Earthworks Industries Inc. (EAATF) Income Statement Analysis – Financial Results
- Otani Kogyo Co.,Ltd. (5939.T) Income Statement Analysis – Financial Results
Lexicon Pharmaceuticals, Inc. (LXRX)
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.20M | 139.00K | 298.00K | 24.00M | 322.07M | 63.21M | 90.34M | 83.34M | 130.01M | 22.85M | 2.22M | 1.09M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 14.46M | 4.70M |
| Cost of Revenue | 85.00K | 427.00K | 55.05M | 1.93M | 3.23M | 2.49M | 1.90M | 163.97M | 95.19M | 89.28M | 89.68M | 82.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.62M | -2.00M |
| Gross Profit | 1.12M | -288.00K | -54.75M | 22.07M | 318.84M | 60.72M | 88.44M | -80.64M | 34.83M | -66.43M | -87.46M | -81.49M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 17.08M | 6.70M |
| Gross Profit Ratio | 92.94% | -207.19% | -18,371.81% | 91.96% | 99.00% | 96.06% | 97.90% | -96.76% | 26.79% | -290.65% | -3,936.09% | -7,482.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 118.13% | 142.55% |
| Research & Development | 58.89M | 52.82M | 55.05M | 153.62M | 91.92M | 100.24M | 156.81M | 178.15M | 95.19M | 89.28M | 89.68M | 82.57M | 91.83M | 75.35M | 81.24M | 108.58M | 104.33M | 106.70M | 93.63M | 90.59M | 82.20M | 74.86M | 53.36M | 31.65M | 14.60M |
| General & Administrative | 0.00 | 48.08M | 0.00 | 0.00 | 0.00 | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 0.00 | 0.00 | 0.00 | 0.00 | 20.86M | 18.29M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 113.98M | 48.08M | 32.34M | 47.23M | 56.84M | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 20.86M | 18.29M | 2.90M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 1.60M | 28.64M | 0.00 | 1.95M | 2.29M | 572.00K | 2.26M | 59.00K | 105.00K | 24.12M | 2.71M | 0.00 | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 275.00M | 2.62M | 4.90M |
| Operating Expenses | 172.87M | 100.90M | 87.39M | 200.85M | 148.76M | 164.00M | 223.02M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 52.56M | 19.50M |
| Cost & Expenses | 172.95M | 100.90M | 87.39M | 202.78M | 151.99M | 166.49M | 224.92M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 49.94M | 17.50M |
| Interest Income | 7.73M | 1.60M | 134.00K | 2.77M | 3.35M | 3.51M | 1.95M | 2.29M | 572.00K | 2.26M | 157.00K | 213.00K | 255.00K | 519.00K | 880.00K | 5.76M | 7.29M | 3.65M | 2.65M | 1.64M | 1.80M | 3.23M | 8.78M | 9.90M | 0.00 |
| Interest Expense | 13.10M | 2.78M | 802.00K | 14.54M | 20.68M | 20.78M | 6.98M | 6.57M | 6.72M | 2.25M | 1.97M | 2.11M | 2.53M | 2.72M | 2.97M | 2.69M | 2.77M | 3.25M | 3.28M | 2.66M | 325.00K | 7.00K | 314.00K | 422.04K | 0.00 |
| Depreciation & Amortization | 554.00K | 427.00K | 292.00K | 2.93M | 3.65M | 3.68M | 3.40M | 2.06M | 727.00K | 1.93M | 2.86M | 4.19M | 4.89M | 5.39M | 6.16M | 10.07M | 10.42M | 11.20M | 11.64M | 12.87M | 21.53M | 20.58M | 16.55M | 2.62M | 2.00M |
| EBITDA | -163.46M | -98.74M | -86.66M | -41.10M | 173.74M | -96.09M | -125.27M | -125.82M | 11.72M | -96.18M | -99.29M | -103.91M | -108.80M | -93.69M | -84.29M | -86.26M | -64.53M | -39.98M | -24.48M | -34.58M | -41.06M | -42.31M | -27.09M | -32.86M | -10.80M |
| EBITDA Ratio | -13,576.74% | -71,341.01% | -29,179.87% | -733.56% | 53.85% | -157.84% | -146.82% | -162.67% | 8.89% | -365.72% | -4,696.89% | -9,018.37% | -6,156.84% | -1,939.67% | -832.49% | -256.94% | -127.18% | -61.03% | -33.09% | -58.12% | -95.86% | -120.21% | -8.86% | -227.24% | -229.79% |
| Operating Income | -171.75M | -100.76M | -87.09M | -178.79M | 141.45M | -103.28M | -136.68M | -137.16M | 1.47M | -100.37M | -102.37M | -108.42M | -114.10M | -95.72M | -89.96M | -96.54M | -74.95M | -55.23M | -36.12M | -47.45M | -62.59M | -62.89M | -43.64M | -35.48M | -12.80M |
| Operating Income Ratio | -14,264.95% | -72,489.21% | -29,224.83% | -745.09% | 43.92% | -163.39% | -151.30% | -164.58% | 1.13% | -439.16% | -4,607.16% | -9,955.46% | -6,170.63% | -1,950.24% | -840.71% | -298.68% | -149.56% | -75.87% | -47.73% | -76.86% | -146.12% | -178.67% | -14.28% | -245.37% | -272.34% |
| Total Other Income/Expenses | -5.37M | -1.18M | -668.00K | -10.77M | -17.33M | -17.27M | -5.03M | -4.27M | -6.15M | 2.00K | -1.76M | -1.80M | -2.12M | -6.08M | -3.46M | -349.00K | 3.72M | 801.00K | -77.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -177.12M | -101.94M | -87.76M | -58.57M | 124.12M | -120.55M | -141.71M | -141.43M | -4.68M | -100.36M | -104.13M | -110.21M | -116.22M | -101.80M | -93.42M | -96.88M | -71.23M | 54.43M | 39.20M | -46.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -14,710.88% | -73,341.01% | -29,448.99% | -244.11% | 38.54% | -190.71% | -156.87% | -169.71% | -3.60% | -439.15% | -4,686.14% | -10,120.39% | -6,285.29% | -2,074.19% | -873.07% | -299.76% | -142.13% | 74.77% | 51.79% | -74.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.18M | 510.00K | 11.61M | -6.01M | 3.51M | -12.66M | 4.51M | 6.00M | -70.00K | -833.00K | -1.97M | -2.36M | -26.00K | -102.00K | -19.68M | -16.16M | -119.00K | 119.00K | -282.00K | 1.61M | -3.22M | -8.47M | -9.48M | -300.00K |
| Net Income | -177.12M | -103.13M | -88.27M | -70.18M | 130.13M | -120.55M | -129.05M | -141.43M | -4.68M | -100.29M | -104.13M | -110.21M | -116.22M | -101.78M | -82.78M | -76.86M | -58.79M | -54.31M | -36.32M | -47.17M | -64.20M | -59.67M | -35.17M | -25.99M | -12.50M |
| Net Income Ratio | -14,710.88% | -74,192.81% | -29,620.13% | -292.49% | 40.40% | -190.71% | -142.86% | -169.71% | -3.60% | -438.85% | -4,686.14% | -10,120.39% | -6,285.29% | -2,073.66% | -773.64% | -237.80% | -117.31% | -74.61% | -47.98% | -76.40% | -149.86% | -169.52% | -11.51% | -179.78% | -265.96% |
| EPS | -0.80 | -0.62 | -0.61 | -0.63 | 1.23 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| EPS Diluted | -0.80 | -0.62 | -0.61 | -0.63 | 1.11 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| Weighted Avg Shares Out | 221.13M | 165.73M | 145.65M | 110.84M | 106.22M | 105.74M | 105.12M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
| Weighted Avg Shares Out (Dil) | 221.13M | 165.73M | 145.65M | 110.84M | 116.75M | 105.83M | 105.24M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
Should You Buy This Growth Stock Right Now Before It Potentially Doubles?
Lexicon is awaiting word from regulators about what could be its first product. Previously, regulators rejected its attempts to commercialize a similar program.
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
THE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of postherpetic neuralgia, will be...
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close. Management will conduct a conference call and live webcast...
Nothing Ever Comes Easy For Lexicon, But Maybe Sotagliflozin Will Prevail In Heart Failure
I discuss Lexicon's long and tumultuous history. Sotagliflozin has a PDUFA in May 2023 for a heart failure indication.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Mike Kelly – Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz –...
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the markets close. Management will conduct a conference call and live webcast...
5 Penny Stocks To Buy For Under $5
Hot penny stocks to watch or buy for under $5? Here's a list of .penny stocks gaining momentum today The post 5 Penny Stocks To Buy For Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information...
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2022 Results - Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Mike Kelly - Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President & Chief Financial Officer Craig Granowitz -...
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast...
Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead
Lexicon has not been lucky with the FDA. However, there are reasons, discussed below, which make me see a special situation here.
Source: https://incomestatements.info
Category: Stock Reports